These clinically challenging breast cancer cases are reminiscent of our findings where loss of PRLR expression in the HR+ MCF-7 cells switched them to a TNBC-like profile with high tumorigenic and metastatic capacities. This evidence concerns the gene PRLR and breast cancer.